^
Association details:
Biomarker:PTEN R233X
Cancer:Melanoma
Drug:Tafinlar (dabrafenib) (BRAF inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
New
Title:

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

Excerpt:
Patient 70 was on therapy for 29 weeks and achieved a partial response before acquiring an NRASQ60H mutation and a PTEN R233* nonsense mutation.
DOI:
10.1158/2159-8290.CD-13-0617